LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | CGP60474 | 10.0 | uM | LJP6 | 2 | G01 | 72 | hr | 1657 | 629 | 5505 | 0.1143 | -0.2674 |
| BT-20 | CGP60474 | 10.0 | uM | LJP6 | 3 | G01 | 72 | hr | 1657 | 680 | 5505 | 0.1235 | -0.2541 |
| BT-20 | CHIR-99021 | 10.0 | uM | LJP6 | 1 | P13 | 72 | hr | 1657 | 5101 | 5505 | 0.9265 | 0.8948 |
| BT-20 | CHIR-99021 | 10.0 | uM | LJP6 | 2 | P13 | 72 | hr | 1657 | 4778 | 5505 | 0.8678 | 0.8109 |
| BT-20 | CHIR-99021 | 10.0 | uM | LJP6 | 3 | P13 | 72 | hr | 1657 | 4639 | 5505 | 0.8426 | 0.7748 |
| BT-20 | CP724714 | 10.0 | uM | LJP5 | 1 | A07 | 72 | hr | 1657 | 3512 | 5505 | 0.6379 | 0.4819 |
| BT-20 | CP724714 | 10.0 | uM | LJP5 | 2 | A07 | 72 | hr | 1657 | 3683 | 5505 | 0.6690 | 0.5263 |
| BT-20 | CP724714 | 10.0 | uM | LJP5 | 3 | A07 | 72 | hr | 1657 | 3845 | 5505 | 0.6984 | 0.5684 |
| BT-20 | CP466722 | 10.0 | uM | LJP5 | 1 | I07 | 72 | hr | 1657 | 3596 | 5505 | 0.6532 | 0.5037 |
| BT-20 | CP466722 | 10.0 | uM | LJP5 | 2 | I07 | 72 | hr | 1657 | 3403 | 5505 | 0.6181 | 0.4536 |
| BT-20 | CP466722 | 10.0 | uM | LJP5 | 3 | I07 | 72 | hr | 1657 | 3588 | 5505 | 0.6517 | 0.5016 |
| BT-20 | Crizotinib | 10.0 | uM | LJP5 | 1 | A19 | 72 | hr | 1657 | 1666 | 5505 | 0.3026 | 0.0021 |
| BT-20 | Crizotinib | 10.0 | uM | LJP5 | 2 | A19 | 72 | hr | 1657 | 1601 | 5505 | 0.2908 | -0.0147 |
| BT-20 | Crizotinib | 10.0 | uM | LJP5 | 3 | A19 | 72 | hr | 1657 | 1671 | 5505 | 0.3035 | 0.0034 |
| BT-20 | Momelotinib | 10.0 | uM | LJP5 | 1 | P07 | 72 | hr | 1657 | 2226 | 5505 | 0.4043 | 0.1477 |
| BT-20 | Momelotinib | 10.0 | uM | LJP5 | 2 | P07 | 72 | hr | 1657 | 2252 | 5505 | 0.4090 | 0.1544 |
| BT-20 | Momelotinib | 10.0 | uM | LJP5 | 3 | P07 | 72 | hr | 1657 | 2162 | 5505 | 0.3927 | 0.1311 |
| BT-20 | Dasatinib | 10.0 | uM | LJP5 | 1 | D01 | 72 | hr | 1657 | 1266 | 5505 | 0.2299 | -0.1018 |
| BT-20 | Dasatinib | 10.0 | uM | LJP5 | 2 | D01 | 72 | hr | 1657 | 1220 | 5505 | 0.2216 | -0.1138 |
| BT-20 | Dasatinib | 10.0 | uM | LJP5 | 3 | D01 | 72 | hr | 1657 | 1365 | 5505 | 0.2479 | -0.0761 |
| BT-20 | Dasatinib | 10.0 | uM | LJP6 | 1 | I01 | 72 | hr | 1657 | 1138 | 5505 | 0.2067 | -0.1351 |
| BT-20 | Dasatinib | 10.0 | uM | LJP6 | 2 | I01 | 72 | hr | 1657 | 1009 | 5505 | 0.1833 | -0.1686 |
| BT-20 | Dasatinib | 10.0 | uM | LJP6 | 3 | I01 | 72 | hr | 1657 | 878 | 5505 | 0.1595 | -0.2026 |
| BT-20 | Dovitinib | 10.0 | uM | LJP5 | 1 | E19 | 72 | hr | 1657 | 2646 | 5505 | 0.4806 | 0.2568 |
| BT-20 | Dovitinib | 10.0 | uM | LJP5 | 2 | E19 | 72 | hr | 1657 | 2430 | 5505 | 0.4414 | 0.2007 |